132 related articles for article (PubMed ID: 2113517)
21. Role of the glycopeptide framework in the antibacterial activity of hydrophobic derivatives of glycopeptide antibiotics.
Printsevskaya SS; Pavlov AY; Olsufyeva EN; Mirchink EP; Preobrazhenskaya MN
J Med Chem; 2003 Mar; 46(7):1204-9. PubMed ID: 12646030
[TBL] [Abstract][Full Text] [Related]
22. Semiquantitation of cooperativity in binding of vancomycin-group antibiotics to vancomycin-susceptible and -resistant organisms.
Beauregard DA; Maguire AJ; Williams DH; Reynolds PE
Antimicrob Agents Chemother; 1997 Nov; 41(11):2418-23. PubMed ID: 9371343
[TBL] [Abstract][Full Text] [Related]
23. [In vitro activity of a new glycopeptide antibiotic eremomycin in relation to obligate anaerobic Gram-positive bacteria].
Malkova IV; Borisova OK; Pavlova MV; Zemlianitskaia EP; Sergeeva TI
Antibiot Khimioter; 1991 Apr; 36(4):17-20. PubMed ID: 1654046
[TBL] [Abstract][Full Text] [Related]
24. Binding of a dimeric derivative of vancomycin to L-Lys-D-Ala-D-lactate in solution and at a surface.
Rao J; Yan L; Lahiri J; Whitesides GM; Weis RM; Warren HS
Chem Biol; 1999 Jun; 6(6):353-9. PubMed ID: 10375541
[TBL] [Abstract][Full Text] [Related]
25. Vancomycin derivatives that inhibit peptidoglycan biosynthesis without binding D-Ala-D-Ala.
Ge M; Chen Z; Onishi HR; Kohler J; Silver LL; Kerns R; Fukuzawa S; Thompson C; Kahne D
Science; 1999 Apr; 284(5413):507-11. PubMed ID: 10205063
[TBL] [Abstract][Full Text] [Related]
26. Antibiotic activities and affinities for bacterial cell wall analogue of N-demethylvancomycin and its derivatives.
Yan H; Qi D; Cheng X; Song Z; Li W; He B
J Antibiot (Tokyo); 1998 Aug; 51(8):750-6. PubMed ID: 9766467
[TBL] [Abstract][Full Text] [Related]
27. Structure, biochemistry and mechanism of action of glycopeptide antibiotics.
Reynolds PE
Eur J Clin Microbiol Infect Dis; 1989 Nov; 8(11):943-50. PubMed ID: 2532132
[TBL] [Abstract][Full Text] [Related]
28. Reversal by a specific peptide (diacetyl-alpha gamma-L-diaminobutyryl-D-alanyl-D-alanine) of vancomycin inhibition in intact bacteria and cell-free preparations.
Nieto M; Perkins HR; Reynolds PE
Biochem J; 1972 Jan; 126(1):139-49. PubMed ID: 4627581
[TBL] [Abstract][Full Text] [Related]
29. Selective cleavage of D-Ala-D-Lac by small molecules: re-sensitizing resistant bacteria to vancomycin.
Chiosis G; Boneca IG
Science; 2001 Aug; 293(5534):1484-7. PubMed ID: 11520986
[TBL] [Abstract][Full Text] [Related]
30. Structure-activity relationship studies of a series of antiviral and antibacterial aglycon derivatives of the glycopeptide antibiotics vancomycin, eremomycin, and dechloroeremomycin.
Printsevskaya SS; Solovieva SE; Olsufyeva EN; Mirchink EP; Isakova EB; De Clercq E; Balzarini J; Preobrazhenskaya MN
J Med Chem; 2005 Jun; 48(11):3885-90. PubMed ID: 15916441
[TBL] [Abstract][Full Text] [Related]
31. Modification and inhibition of vancomycin group antibiotics by formaldehyde and acetaldehyde.
Heck AJ; Bonnici PJ; Breukink E; Morris D; Wills M
Chemistry; 2001; 7(4):910-6. PubMed ID: 11288883
[TBL] [Abstract][Full Text] [Related]
32. [Experimental study of the antibacterial activity and chemotherapeutic efficacy of the novel glycopeptide eremomycin].
Malikova IV
Antibiot Khimioter; 1989 Jan; 34(1):52-6. PubMed ID: 2543344
[TBL] [Abstract][Full Text] [Related]
33. Getting closer to the real bacterial cell wall target: biomolecular interactions of water-soluble lipid II with glycopeptide antibiotics.
Vollmerhaus PJ; Breukink E; Heck AJ
Chemistry; 2003 Apr; 9(7):1556-65. PubMed ID: 12658654
[TBL] [Abstract][Full Text] [Related]
34. In-vitro characteristics of glycopeptide resistant strains of Staphylococcus epidermidis isolated from patients on CAPD.
Sanyal D; Johnson AP; George RC; Edwards R; Greenwood D
J Antimicrob Chemother; 1993 Aug; 32(2):267-78. PubMed ID: 8226428
[TBL] [Abstract][Full Text] [Related]
35. Reductive alkylation of glycopeptide antibiotics: synthesis and antibacterial activity.
Cooper RD; Snyder NJ; Zweifel MJ; Staszak MA; Wilkie SC; Nicas TI; Mullen DL; Butler TF; Rodriguez MJ; Huff BE; Thompson RC
J Antibiot (Tokyo); 1996 Jun; 49(6):575-81. PubMed ID: 8698642
[TBL] [Abstract][Full Text] [Related]
36. Total synthesis and evaluation of [Psi[CH2NH]Tpg4]vancomycin aglycon: reengineering vancomycin for dual D-Ala-D-Ala and D-Ala-D-Lac binding.
Crowley BM; Boger DL
J Am Chem Soc; 2006 Mar; 128(9):2885-92. PubMed ID: 16506767
[TBL] [Abstract][Full Text] [Related]
37. In vitro antistaphylococcal activity of dalbavancin, a novel glycopeptide.
Lopez S; Hackbarth C; Romanò G; Trias J; Jabes D; Goldstein BP
J Antimicrob Chemother; 2005 Mar; 55 Suppl 2():ii21-4. PubMed ID: 15750033
[TBL] [Abstract][Full Text] [Related]
38. Nuclear magnetic resonance studies on the interaction of avoparcin with model receptors of bacterial cell walls.
Fesik SW; Armitage IM; Ellestad GA; McGahren WJ
Mol Pharmacol; 1984 Mar; 25(2):281-6. PubMed ID: 6700574
[TBL] [Abstract][Full Text] [Related]
39. Microbiological properties of teicoplanin.
Greenwood D
J Antimicrob Chemother; 1988 Jan; 21 Suppl A():1-13. PubMed ID: 2965119
[TBL] [Abstract][Full Text] [Related]
40. Mechanism of action of oritavancin and related glycopeptide antibiotics.
Allen NE; Nicas TI
FEMS Microbiol Rev; 2003 Jan; 26(5):511-32. PubMed ID: 12586393
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
